Characterization of [H]LUF5834: a novel non-ribose high-affinity agonist radioligand for the adenosine A receptor

• Published in: Biochemical pharmacology Vol. 80; no. 8
• Main Authors: Lane, J. Robert, Klaasse, Elisabeth, Lin, Judy, van Bruchem, John, Beukers, Margot W., Ijzerman, Adriaan P.
• Format: Journal Article
• Language: English
• Published: Elsevier 15.10.2010
• Subjects: G protein-coupled receptor; adenosine receptor; radioligand; partial agonist; inverse agonist
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2010.06.041

The adenosine A receptor is a promising therapeutic target for neurological disorders such as cognition deficits and is involved in cardiovascular preconditioning. Classically adenosine receptor agonists were all derivatives of adenosine, and thought to require a D-ribose moiety. More recently, however, the discovery of non-adenosine agonists for the human adenosine A receptor (hAR) has challenged this dogma (Beukers et al. 2004). In this study we characterize the tritiated form of one of these compounds, [H]LUF5834, as the first non-ribose partial agonist radioligand with nanomolar affinity for the hAR. Due to its partial agonist efficacy, [H]LUF5834 labeled both G protein-coupled and uncoupled receptors with a similar high affinity. Using [H]LUF5834 we performed competition binding experiments to characterize a range of AR ligands varying in efficacy from the full agonist CPA to the inverse agonist DPCPX. Surprisingly, in the control condition both agonists and inverse agonists displayed biphasic isotherms. With the addition of 1mM GTP the high affinity isotherm of agonists or the low affinity isotherm of inverse agonists was lost revealing the mechanism of action of such inverse agonists at the AR. Consequently, [H]LUF5834 represents a novel high affinity radioligand for the AR and may prove a useful tool to provide estimates of inverse agonist efficacy at this receptor.